A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The S&P 500 added 0.9% on Monday, June 16, as investors absorbed the possibility of cooling geopolitical tensions and looked ...

Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ETCompany ParticipantsLavina Talukdar - Senior VP ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The drugmaker plans to ask for FDA approval of the vaccine this year, while other pharmaceutical companies are also working on RSV vaccines. CNBC: Moderna: RSV Vaccine Effective In Preventing Disease ...

Public health and infectious disease experts said they were surprised and confused about the move, and questioned why the HHS ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

According to the Alzheimer’s Association, today in America, 7 million people are living with the condition. It is believed ...

( The Hill) — The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...